Engineered cancer-derived small extracellular vesicle-liposome hybrid delivery system for targeted treatment of breast cancer

Wei Zhang, Long Ngo, Simon Chang-Hao Tsao, Dingbin Liu*, Yuling Wang*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Cancer-derived small extracellular vesicles (sEVs) may be a promising drug delivery system that targets cancer cells due to their unique features, such as native homing ability, biological barrier crossing capability, and low immune response. However, the oncogenic cargos within them pose safety concerns, hence limiting their application thus far. We proposed using an electroporation-based strategy to extract the endogenous cargos from cancer-derived sEVs and demonstrated that their homing ability was still retained. A membrane fusion technique was used to fuse these sEVs with liposomes to form hybrid particles, which possessed both benefits of sEVs and liposomes. Anti-EGFR monoclonal antibodies were modified on the hybrid particles to improve their targeting ability further. The engineered hybrid particles showed higher drug loading ability that is 33.75 and 43.88% higher than that of liposomes and sEVs, respectively, and improved targeting ability by 52.23% higher than hybrid particles without modification. This delivery system showed >90% cell viability and enhanced treatment efficiency with 91.58 and 79.26% cell migration inhibition rates for the miR-21 inhibitor and gemcitabine, respectively.
Original languageEnglish
Pages (from-to)16420-16433
Number of pages14
JournalACS Applied Materials and Interfaces
Volume15
Issue number13
Early online date24 Mar 2023
DOIs
Publication statusPublished - 5 Apr 2023

Keywords

  • extracellular vesicles
  • liposomes
  • hybrid particles
  • electroporation
  • drug delivery system
  • miRNA inhibitor
  • breast cancer

Fingerprint

Dive into the research topics of 'Engineered cancer-derived small extracellular vesicle-liposome hybrid delivery system for targeted treatment of breast cancer'. Together they form a unique fingerprint.

Cite this